Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. (Q40406835)
scientific article published on 8 July 2005
Language:
(P31) (Q13442814)
(P50) (Q59594064)
(P304) 1688-1694
(P433) 10
(P478) 16
(P577) Friday, July 8, 2005
(P921) (Q181600)
(Q323936)
(P1433) (Q326122)
(P1476) "Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors" (language: en)
(P2093) M Moore
H W Hirte
L Siu
A Oza
S J Hotte
O Petrenciuc
F Cihon
C Lathia
(P2860) (Q27860760)
other details
description scientific article published on 8 July 2005

External Links